- Home
- CHNR vs MBRX Comparison
CHNR vs MBRX Comparison
Compare CHNR & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$4.10
HOLD
Current Price
$2.30
Company Overview
Basic Information| Metric | CHNR | MBRX |
|---|---|---|
| Founded | N/A | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 6.1M |
| IPO Year | 1996 | 2016 |
Fundamental Metrics
Financial Performance| Metric | CHNR | MBRX |
|---|---|---|
| Price | $4.10 | $2.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $61.00 |
| AVG Volume (30 Days) | ★ 768.7K | 108.6K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.45 | $0.25 |
| 52 Week High | $57.47 | $7.98 |
Technical Indicators
Market Signals| Indicator | CHNR | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 50.43 | 45.74 |
| Support Level | $3.31 | $0.37 |
| Resistance Level | $4.25 | $2.52 |
| Average True Range (ATR) | 0.55 | 0.14 |
| MACD | -0.01 | 0.08 |
| Stochastic Oscillator | 32.82 | 63.64 |
Price Performance
Historical Comparison CHNR
MBRX
About CHNR China Natural Resources Inc.
China Natural Resources Inc is engaged in exploration for lead, silver, and other metals in the Inner Mongolia Autonomous Region of the PRC and exploration of attractive opportunities in other sectors. The company has a single operating segment: exploration and mining.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.